Drug intelligence / Profile preview

carnosol

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral
01

Overview

Carnosol is a naturally occurring **phenolic diterpene** found primarily in rosemary (Rosmarinus officinalis) and sage (Salvia carnosa)[1][2][4]. It is a product of the oxidative degradation of carnosic acid and is characterized by an abietane carbon skeleton with ortho-diphenolic and lactone moieties[1]. Carnosol exhibits a range of biological and pharmacological activities including potent **antioxidant, anti-inflammatory, antimicrobial, and anticarcinogenic effects**[1][4][5][7]. Mechanistically, it acts as: - An inhibitor of **cyclooxygenase-2 (COX-2) induction** by blocking protein kinase C (PKC) signaling, - A **dual antagonist** of the **androgen receptor (AR)** and **estrogen receptor alpha (ERα)**, - An inhibitor of **5-lipoxygenase (5-LO)** and leukotriene synthesis[4][5]. Carnosol also targets heat-shock protein 90 (**HSP90**), inhibiting its ATPase activity to block activation of the **NLRP3 inflammasome** and thereby modulating inflammation[3]. It activates **peroxisome proliferator-activated receptor gamma (PPARγ)** and suppresses multiple pro-inflammatory and tumorigenic signaling pathways including NF-κB and MAPKs[5]. Preclinical studies have demonstrated **chemopreventive effects** in various cancer models (e.g., prostate, breast, skin, leukemia, colon), and efficacy in animal models of **NASH** and **sepsis**[1][3][5]. Carnosol is widely used in research and as a nutraceutical ingredient, but it is **not approved as a pharmaceutical drug** in any jurisdiction as of August 2025[1][5].

Other names
5957-80-2carnolcarnosolcarnosol-RMcarnosol-RG
02

Targets

ALOX12 (Arachidonate 12-lipoxygenase, 12S type)AR (Adrenergic receptors)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ER (Estrogen receptor)NF-κBPTGES (Microsomal prostaglandin E synthase-1)HSP90AA1 (Heat shock protein HSP90-alpha)PPARG (Peroxisome proliferator-activated receptor gamma)

Beyond the preview

Go deeper on carnosol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on carnosol.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call